La Jolla, CA, United States
Orexigen Therapeutics, Inc. recalls
2 recalls recorded since 2018, most recently on 5 October 2018. None are listed as ongoing. Status and classification are as published by the FDA.
Recalls2
Ongoing (FDA)0
Terminated or completed2
Class I (FDA)0
Terminated Class III Drugs
- Recall started
- 5 October 2018
- Terminated
- 15 November 2019
- Reason
- Container packaging defect.
- Distribution
- Within the United States
- Initiated
- Voluntary: Firm initiated
- Recall number
- D-0219-2019
- Contrave (naltrexone HCl and bupropion HCl). Extended-Release Tablets, 8mg/90 mg, 120-count bottles, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA 92037, NDC 51267-890-99
Terminated Class III Drugs
- Recall started
- 9 August 2018
- Terminated
- 15 November 2019
- Reason
- Defective Container: Customer complaints of punctures in the bottle.
- Distribution
- Nationwide in the USA
- Initiated
- Voluntary: Firm initiated
- Recall number
- D-1099-2018
- Contrave (naltrexone HCl and bupropion HCl) Extended-Release Tablets, 8 mg/90 mg, 120-count bottle, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA 92037, NDC 51267-890-99.
A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.